Technology ID
TAB-2657

Development of Immune System Tolerance for the Treatment of Autoimmune Disease

E-Numbers
E-186-2009-0
Lead Inventor
Chen, Wanjun (NIDCR)
Applications
Therapeutics
Research Materials
Diagnostics
Therapeutic Areas
Immunology
Development Status
  • Early-stage
  • In vivo data available (animal)
Lead IC
NIDCR
ICs
NIDCR
The present invention provides a therapeutic method for the treatment of autoimmune or autoinflammatory diseases by first breaking down the dysregulated immune system and then reprogramming the immune system to restore tolerance to the patient's self-antigens by induction of antigen specific regulatory T cells. The inventors have shown that only with the combination of apoptosis, phagocytes, and antigen can antigen-specific regulatory T cells (Treg) cells be optimally generated to develop long-term immune tolerance. This strategy for developing immune tolerance can be applied to the treatment of autoimmune diseases.
Commercial Applications
  • Treatment of autoimmune disease.
Competitive Advantages
  • This technology represents a novel means of treating autoimmune disease.

Request More Info

Licensing Contact:
Yonter, Ediz
ediz.yonter@nih.gov

Patents

  • US
    National Stage 14/904,054
    Filed on 2016-01-08
  • US
    Provisional (PRV) 61/844,564
    Filed on 2013-07-10
  • Patent Cooperation Treaty
    (PCT) PCT/US14/046065
    Filed on 2014-07-10
  • US
    Continuation (CON) 16/773,982
    Filed on 2020-01-27
  • US
    Continuation (CON) 17/167,737
    Filed on 2021-02-04
Date Published